Sobi’s full year 2019 revenue and EBITA higher than previous estimates
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announces today that revenue and EBITA for the full year 2019 were higher than previous estimates. Full-year revenue was approximately SEK 14,150 –14,250 M and EBITA approximately SEK 6,200 – 6,300 M, excluding restructuring costs and excluding impact from the acquisition of Dova Pharmaceuticals. The main reasons for the better performance are: · Significantly higher sales of Synagis following increased demand as a